Bluejay Diagnostics Files 8-K on Material Agreement, Other Events

Ticker: BJDX · Form: 8-K · Filed: 2024-01-02T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, corporate-action, 8-K

TL;DR

**Bluejay Diagnostics just filed an 8-K about a new material agreement, watch for details.**

AI Summary

Bluejay Diagnostics, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 27, 2023. This filing indicates the company entered into a material definitive agreement and also covers other events and financial statements/exhibits. As an emerging growth company, this filing signals significant corporate activity that could impact its future operations and financial health, which is crucial for investors to monitor.

Why It Matters

This filing signals a significant corporate action by Bluejay Diagnostics, Inc. that could affect its financial position and future prospects, making it important for current and potential investors to understand the details of the material definitive agreement.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative, introducing uncertainty until specific details are disclosed.

Analyst Insight

Investors should await further details regarding the 'Material Definitive Agreement' mentioned in the filing to assess its potential impact on Bluejay Diagnostics, Inc.'s financial health and future prospects before making any investment decisions.

Key Players & Entities

FAQ

What was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on December 27, 2023.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on January 2, 2024.

What specific items were reported in this 8-K filing by Bluejay Diagnostics, Inc.?

The 8-K filing reported 'Entry into a Material Definitive Agreement,' 'Other Events,' and 'Financial Statements and Exhibits'.

Is Bluejay Diagnostics, Inc. considered an emerging growth company?

Yes, Bluejay Diagnostics, Inc. indicated by check mark that it is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

What is the business address of Bluejay Diagnostics, Inc. as stated in the filing?

The business address of Bluejay Diagnostics, Inc. is 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

Filing Stats: 1,303 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2024-01-02 17:21:42

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events. On December 28, 2023, the Company issued a press release announcing the pricing of the Offering. On January 2, 2024, the Company issued a press release announcing the closing of the Offering. Copies of the press releases are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are hereby incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Prefunded Warrant 4.2 Form of Warrant 4.3 Form of Placement Agent Warrant 10.1 Form of Securities Purchase Agreement 99.1 Press Release dated December 28, 2023 99.2 Press Release dated January 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BLUEJAY DIAGNOSTICS, INC. Date: January 2, 2024 By: /s/ Neil Dey Name: Neil Dey Title: Chief Executive Officer 3

View on Read The Filing